Clinical effectiveness of medical ozone therapy in COVID-19 : the evidence and gaps map
Ozone therapy (OT), a medical procedure, has been showing good results during the coronavirus disease (COVID-19). We aimed to build an evidence and gaps map (EGM) of OT in the COVID-19 ranking the articles found according to levels of evidence and outcomes. The EGM brings bubbles of different sizes and different colors according to the articles. The OT intervention used was major or minor autohemotherapy, rectal insufflation and ozonized saline solution. EGM was based on 13 clinical studies using OT for COVID-19 involving a total of 271 patients. We found 30 outcomes related to OT in COVID-19. Our EGM divided the outcomes into six groups: 1-clinical improvement; 2-hospitalization; 3-inflammatory, thromboembolic, infectious, or metabolic markers; 4-radiological aspects, 5-viral infection and 6-adverse events. Major autohemotherapy was present in 19 outcomes, followed by rectal insufflation. Improvement in clinical symptoms of COVID-19, improvement of respiratory function, improvement of oxygen saturation, reduction in hospital internment, decrease in C-reactive protein, decrease in ferritin, decrease in lactate dehydrogenase, decrease in interleukin 6, decrease in D-dimer, radiological improvement of lung lesions and absence of reported adverse events were related in the papers. The most commonly used concentrations of OT in major autohemotherapy and in rectal insufflation were 40 μg/mL and 35 μg/mL, respectively. Here, we bring the first EGM showing the efficacy and safety of OT in the treatment of COVID-19. OT can be used as integrative medical therapy in COVID-19 at a low cost and improve the health conditions of the patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Medical gas research - 13(2023), 4 vom: 14. Okt., Seite 172-180 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Serra, Maria Emilia Gadelha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
66H7ZZK23N |
|---|
| Anmerkungen: |
Date Completed 21.04.2023 Date Revised 31.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.4103/2045-9912.372819 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355809273 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355809273 | ||
| 003 | DE-627 | ||
| 005 | 20231226210251.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/2045-9912.372819 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355809273 | ||
| 035 | |a (NLM)37077114 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Serra, Maria Emilia Gadelha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical effectiveness of medical ozone therapy in COVID-19 |b the evidence and gaps map |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2023 | ||
| 500 | |a Date Revised 31.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Ozone therapy (OT), a medical procedure, has been showing good results during the coronavirus disease (COVID-19). We aimed to build an evidence and gaps map (EGM) of OT in the COVID-19 ranking the articles found according to levels of evidence and outcomes. The EGM brings bubbles of different sizes and different colors according to the articles. The OT intervention used was major or minor autohemotherapy, rectal insufflation and ozonized saline solution. EGM was based on 13 clinical studies using OT for COVID-19 involving a total of 271 patients. We found 30 outcomes related to OT in COVID-19. Our EGM divided the outcomes into six groups: 1-clinical improvement; 2-hospitalization; 3-inflammatory, thromboembolic, infectious, or metabolic markers; 4-radiological aspects, 5-viral infection and 6-adverse events. Major autohemotherapy was present in 19 outcomes, followed by rectal insufflation. Improvement in clinical symptoms of COVID-19, improvement of respiratory function, improvement of oxygen saturation, reduction in hospital internment, decrease in C-reactive protein, decrease in ferritin, decrease in lactate dehydrogenase, decrease in interleukin 6, decrease in D-dimer, radiological improvement of lung lesions and absence of reported adverse events were related in the papers. The most commonly used concentrations of OT in major autohemotherapy and in rectal insufflation were 40 μg/mL and 35 μg/mL, respectively. Here, we bring the first EGM showing the efficacy and safety of OT in the treatment of COVID-19. OT can be used as integrative medical therapy in COVID-19 at a low cost and improve the health conditions of the patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-COV-2 | |
| 650 | 4 | |a complementary therapies | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a evidence and gaps map | |
| 650 | 4 | |a evidence map | |
| 650 | 4 | |a medical ozone therapy | |
| 650 | 4 | |a medicinal ozone | |
| 650 | 4 | |a ozone | |
| 650 | 4 | |a ozone therapy | |
| 650 | 7 | |a Ozone |2 NLM | |
| 650 | 7 | |a 66H7ZZK23N |2 NLM | |
| 700 | 1 | |a Baeza-Noci, José |e verfasserin |4 aut | |
| 700 | 1 | |a Abdala, Carmen Verônica Mendes |e verfasserin |4 aut | |
| 700 | 1 | |a Luvisotto, Marilia Moura |e verfasserin |4 aut | |
| 700 | 1 | |a Bertol, Charise Dallazem |e verfasserin |4 aut | |
| 700 | 1 | |a Anzolin, Ana Paula |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical gas research |d 2012 |g 13(2023), 4 vom: 14. Okt., Seite 172-180 |w (DE-627)NLM216076978 |x 2045-9912 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:4 |g day:14 |g month:10 |g pages:172-180 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/2045-9912.372819 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 4 |b 14 |c 10 |h 172-180 | ||